Request a quote
Request a quote
Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more
Country of origin

Sulindac API from Indian Manufacturers & Suppliers

2 verified results
When insight is your advantage
Full data, full access, full negotiation power
Get full access Get full access
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison

Commercial-scale Suppliers

India

Producer
Produced in  India
|
Audit Report: Click here for more information on Eurofins audit reports
Certifications: USDMF
|
CoA
|
WC

All certificates

USDMF
CoA
WC
Not active

United Kingdom

Producer
Produced in  India
|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
WC
|
CoA

All certificates

GMP
WC
CoA
Not active
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Start a Special Inquiry Get full access
Get full market intelligence report
Get full market intelligence report
€399,-
All Sulindac data. Full access. Full negotiation power
Get my report Get my report
When insight is your advantage
Full data, full access, full negotiation power
Get full access Get full access
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Sulindac | CAS No: 38194-50-2 | GMP-certified suppliers

A medication that provides relief from pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis.

Therapeutic categories

Acetic Acid Derivatives and Related SubstancesAgents causing hyperkalemiaAgents that produce hypertensionAnalgesicsAnalgesics, Non-NarcoticAnti-Inflammatory Agents
Generic name
Sulindac
Molecule type
small molecule
CAS number
38194-50-2
DrugBank ID
DB00605
Approval status
Approved drug, Investigational drug
ATC code
M01AB02

Primary indications

  • For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis

Product Snapshot

  • Sulindac is supplied as oral tablets and rectal suppositories for small‑molecule solid‑dose formulations
  • It is used for symptomatic management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder conditions, and acute gouty arthritis
  • It is approved in the US and Canada, with both approved and investigational regulatory designations

Clinical Overview

Sulindac, CAS 38194-50-2, is a nonsteroidal anti-inflammatory drug belonging to the arylalkanoic acid and indene derivative classes. It is indicated for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis. It has been marketed under the brand name Clinoril in several regions.

Sulindac functions as a prodrug. Following oral administration, it undergoes hepatic reduction to form an active sulfide metabolite, while an inactive sulfone metabolite is also generated. The sulfide metabolite participates in enterohepatic circulation, which contributes to sustained systemic exposure. This metabolic pathway may influence gastrointestinal tolerability compared with some other nonselective NSAIDs.

Pharmacologically, sulindac provides anti-inflammatory, analgesic, and antipyretic effects. Its clinical activity is attributed primarily to reversible inhibition of cyclooxygenase isoenzymes COX‑1 and COX‑2, resulting in reduced prostaglandin synthesis. Antipyretic activity is associated with hypothalamic action leading to enhanced peripheral vasodilation and heat dissipation. Although the precise molecular determinants of its activity are not fully clarified, its pharmacodynamic profile is consistent with other nonselective NSAIDs.

Absorption occurs after oral dosing, with metabolism predominantly in the liver. The active metabolite reaches measurable systemic concentrations and exhibits high plasma protein binding. Elimination occurs through both biliary and renal routes, reflecting contributions from enterohepatic recycling and renal excretion of metabolites. Pharmacokinetic performance may be altered in hepatic impairment due to its reliance on metabolic activation.

Safety considerations align with the nonselective NSAID class. Clinically relevant risks include gastrointestinal ulceration or bleeding, renal function effects, fluid retention, hypertension, and rare photosensitivity reactions. Sulindac has also been associated with hyperkalemia in susceptible populations. Caution is advised in patients with compromised renal or hepatic function and in those receiving concomitant nephrotoxic or protein‑binding–competitive therapies.

For API procurement, sourcing should prioritize suppliers with demonstrated control of stereochemical integrity, impurity profiles related to sulfinyl and sulfide forms, and robust stability data appropriate for global regulatory submission.

Identification & chemistry

Generic name Sulindac
Molecule type Small molecule
CAS 38194-50-2
UNII 184SNS8VUH
DrugBank ID DB00605

Pharmacology

SummarySulindac is a nonsteroidal anti‑inflammatory agent whose activity is primarily attributed to inhibition of COX‑1 and COX‑2, reducing prostaglandin synthesis involved in inflammation, pain, and fever. It may also influence hypothalamic pathways related to thermoregulation and interacts with additional targets such as aldose reductase, MAPK3, PPAR‑δ, and prostaglandin receptors. These combined actions support its use in conditions characterized by inflammatory pain.
Mechanism of actionSulindac's exact mechanism of action is unknown. Its antiinflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
PharmacodynamicsSulindac is a non-steroidal anti-inflammatory indene derivative, also possessing analgesic and antipyretic activities.
Targets
TargetOrganismActions
Prostaglandin G/H synthase 2Humansinhibitor
Prostaglandin G/H synthase 1Humansinhibitor
Aldose reductaseHumansinhibitor

ADME / PK

AbsorptionApproximately 90% absorbed in humans following oral administration.
Half-lifeThe mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.
Protein bindingAt 1 mcg/ml concentrations, approximately 93% sulindac and 98% of its sulfide metabolite are bound to human serum albumin.
MetabolismUndergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Sulindac and its sulfide and sulfone metabolites undergo extensive enterohepatic circulation. Available evidence indicates that the biological activity resides with the sulfide metabolite. Side chain hydroxylation and hydration of the double bond also occur.
Route of eliminationSulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk. Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Hepatic metabolism is an important elimination pathway.
Clearance* Renal cl=68.12 +/- 27.56 mL/min [NORMAL (19-41 yrs)]

Formulation & handling

  • Low aqueous solubility supports conventional oral solid formulations but may require attention to dissolution performance for consistent exposure.
  • As a small‑molecule NSAID, it is suitable for standard tablet processing, with typical sensitivity to gastric irritation influencing co‑formulation with protective excipients.
  • Food co‑administration considerations indicate a need to assess the impact of fed‑state conditions on dissolution and GI tolerability during formulation development.

Regulatory status

LifecyclePatent protection for this API has either expired or is approaching expiry, suggesting a mature market environment. In Canada and the US, the product landscape reflects established competition consistent with late‑lifecycle status.
MarketsCanada, US
Supply Chain
Supply chain summarySulindac originated from a single research‑based developer, with subsequent supply dominated by multiple generic manufacturers that formulate and distribute the active ingredient. Branded products such as Clinoril have been marketed mainly in the US and Canada, while numerous packagers support broad distribution. Patent expiry has long passed, and the presence of many established generic producers indicates mature generic competition.

Safety

ToxicityAcute oral toxicity (LD<sub>50</sub>) in rats is 264 mg/kg. Cases of overdose have been reported and rarely, deaths have occurred. The following signs and symptoms may be observed following overdose: stupor, coma, diminished urine output and hypotension.
High Level Warnings:
  • Exhibits moderate acute oral toxicity in rats (LD50 ~264 mg/kg), indicating the need for controlled handling and exposure minimization in manufacturing settings
  • Overdose data associate the compound with CNS depression (stupor, coma) and systemic effects such as reduced urine output and hypotension, underscoring the importance of preventing high-level exposure
  • Personnel should manage the API to avoid conditions that could lead to significant systemic absorption, given the documented severe outcomes in accidental or excessive exposure

Sulindac is a type of NSAIDs


NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are a widely used subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs). These medications are commonly prescribed for their analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. NSAIDs work by inhibiting the production of certain enzymes called cyclooxygenases (COX), which play a crucial role in the synthesis of prostaglandins, substances that contribute to pain, inflammation, and fever.

These pharmaceutical APIs are available in various formulations, including tablets, capsules, creams, and gels, making them convenient for different administration routes. Some popular examples of NSAIDs include aspirin, ibuprofen, naproxen, and diclofenac.

NSAIDs are commonly used to treat a wide range of conditions such as arthritis, musculoskeletal injuries, dental pain, menstrual pain, and headaches. They are also effective in managing inflammatory conditions like rheumatoid arthritis and ankylosing spondylitis.

While NSAIDs are generally safe and effective when used as directed, they may have side effects. These can include gastrointestinal issues such as stomach ulcers or bleeding, cardiovascular risks, and kidney problems. Therefore, it is essential to follow the recommended dosage and consult with healthcare professionals to ensure proper and safe usage.

In conclusion, NSAIDs are a subcategory of pharmaceutical APIs that offer analgesic, anti-inflammatory, and antipyretic properties. Their versatility and effectiveness in treating various conditions make them widely prescribed medications. However, it is crucial to be aware of potential side effects and consult healthcare providers for appropriate usage.


Sulindac (NSAIDs), classified under Anti-inflammatory Agents


Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.

Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.

Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.

In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.



Sulindac API manufacturers & distributors

Compare qualified Sulindac API suppliers worldwide. We currently have 2 companies offering Sulindac API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Producer
United Kingdom India CoA, GMP, WC31 products
Producer
India India CoA, USDMF, WC44 products

When sending a request, specify which Sulindac API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Sulindac API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.

We show synonyms and CAS numbers for Sulindac API to help you connect with the right supplier. However, a synonym or CAS number does not always mean it is exactly the same specification. Always confirm the final specs directly with the supplier before placing an order.

Frequently asked questions about Sulindac API


Sourcing

What matters most when sourcing GMP-grade Sulindac?
Key considerations include confirming that the supplier complies with U.S. and Canadian GMP requirements and can provide complete regulatory and quality documentation. Given the mature generic market, it is important to verify the manufacturer’s qualification, consistency of production, and traceability within the supply chain. Assessing batch-to-batch quality, change‑control practices, and reliability of supply helps ensure suitability for pharmaceutical use.
Which documents are typically required when sourcing Sulindac API?
Request the core API documentation set: CoA (2 companies), WC (2 companies), USDMF (1 company), GMP (1 company). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Sulindac API?
Known or reported manufacturers for Sulindac: . Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Sulindac API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Sulindac manufacturers?
Audit reports may be requested for Sulindac: 1 GMP audit report available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Sulindac API on Pharmaoffer?
Reported supplier count for Sulindac: 2 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Sulindac API?
Production countries reported for Sulindac: India (2 producers). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Sulindac usually hold?
Common certifications for Sulindac suppliers: CoA (2 companies), WC (2 companies), USDMF (1 company), GMP (1 company). Always verify issuing authorities and expiry dates when reviewing audit packages.

Technical

What is Sulindac (CAS 38194-50-2) used for?
Sulindac is used to manage pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis. It acts as a nonselective NSAID, functioning as a prodrug whose active sulfide metabolite inhibits COX‑1 and COX‑2 to reduce prostaglandin synthesis.
Which therapeutic class does Sulindac fall into?
Sulindac belongs to the following therapeutic categories: Acetic Acid Derivatives and Related Substances, Agents causing hyperkalemia, Agents that produce hypertension, Analgesics, Analgesics, Non-Narcotic. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Sulindac mainly prescribed for?
The primary indications for Sulindac: For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Sulindac work?
Sulindac's exact mechanism of action is unknown. Its antiinflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
What should someone know about the safety or toxicity profile of Sulindac?
Sulindac shows moderate acute oral toxicity in rats, and high-level exposure or overdose has been associated with CNS depression, reduced urine output, and hypotension. As with other nonselective NSAIDs, clinically relevant risks include gastrointestinal ulceration or bleeding, renal effects, fluid retention, hypertension, photosensitivity, and possible hyperkalemia in susceptible individuals. Handling of the API should limit systemic absorption, and use in patients with renal or hepatic impairment warrants caution due to its metabolic and elimination pathways.
What are important formulation and handling considerations for Sulindac as an API?
Important considerations include managing Sulindac’s low aqueous solubility, which may require dissolution‑enhancing strategies to ensure consistent oral absorption. Standard tablet processing is generally suitable, but excipients should be selected to address its potential for gastric irritation. Fed‑state effects on dissolution and gastrointestinal tolerability should be evaluated during development to support reliable in‑use performance.
Is Sulindac a small molecule?
Sulindac is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Sulindac?
Oral Sulindac has low aqueous solubility, so formulations may require attention to dissolution performance to maintain consistent exposure. Its typical NSAID sensitivity to gastric irritation can influence excipient selection but does not imply unusual chemical instability. Fed‑state conditions may affect dissolution and should be assessed during development. Beyond these factors, no special stability concerns are indicated in the provided information.

Regulatory

Where is Sulindac approved or in use globally?
Sulindac is reported as approved in the following major regions: Canada, US. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
What’s the regulatory and patent landscape for Sulindac right now?
Sulindac is an established NSAID with regulatory approval in both the United States and Canada. It is marketed in generic form, and the original patents have long expired. No active patent protections are associated with standard Sulindac products in these markets.

Pharmaoffer

How does Pharmaoffer’s Smart Sourcing Service help with Sulindac procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Sulindac. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Sulindac included in the PRO Data Insights coverage?
PRO Data Insights coverage for Sulindac: 348 verified transactions across 65 suppliers and 72 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Sulindac?
Market report availability for Sulindac: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.